Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-CAT-I: REGN7508 for primary prophylaxis of cancer-associated thrombosis in adults with solid tumors
2024-519298-21-00Phase 3Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in cancer-associated thrombosis (CAT) comparing Cenvacibart with Placebo matching REGN7508 (2 arms). Planned start Apr 2026; status: authorised.
02
Drugs
cenvacibart
03
Conditions
cancer-associated thrombosis (CAT)
Beyond the preview
Go deeper on 2024-519298-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519298-21-00.